Park­er In­sti­tute backs an up­start biotech look­ing to de­vel­op a new, con­vert­ible CAR-T

The bil­lion­aire-backed Park­er In­sti­tute for Can­cer Im­munother­a­py is in­vest­ing and part­ner­ing with a biotech their re­searchers be­lieve has the po­ten­tial to de­vel­op a new-mod­el CAR-T that can be bet­ter guid­ed down nar­row path­ways and equipped with a con­ve­nient on/off switch to help avoid any fa­tal ac­ci­dents.

Park­er CEO Jef­frey Blue­stone isn’t giv­ing away any num­bers right now, but he says the in­sti­tute’s eq­ui­ty in­vest­ment in Xyphos Bio­sciences “isn’t triv­ial.” The pri­ma­ry pur­pose of the in­vest­ment — and the re­search al­liance that plugs Xyphos in­to their net­work of promi­nent in­ves­ti­ga­tors — is to ac­cel­er­ate the work and pre­vent it from get­ting stuck in the R&D mud.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER